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Electrical Stimulation for the Treatment of Obstructive Sleep Apnoea: 
Review of the Evidence  
 
Abstract 
Introduction: Obstructive sleep apnoea is an increasingly prevalent clinical condition with 
significant impact on individuals and public health. Continuous positive airway pressure 
therapy is the standard treatment, but adherence is limited and alternative treatments are 
needed. In this context, non-invasive and invasive methods for electrical stimulation of 
upper airway dilator muscles have been demonstrated to be effective in selected patients.   
Areas covered: Investigations on the clinical effects, safety, and tolerability of non-invasive 
and invasive electrical stimulation of the upper airway for the management of obstructive 
sleep apnoea. Following a search of the relevant literature published on Pub Med this 
review is focused mainly on data obtained from randomized clinical trials and clinical 
studies.  
Expert commentary: The available evidence provides a rationale to consider upper airway 
electrical stimulation as treatment for selected patients with obstructive sleep apnoea, who 
have poor adherence or experience difficulties with continuous positive airway pressure 
therapy. Non-invasive stimulation using transcutaneous electrodes and implantable 
hypoglossal nerve stimulator technologies may provide an alternative to continuous 
positive airway pressure for the treatment of obstructive sleep apnoea via restoration of 
neuromuscular tone and improved upper airway patency.  
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1. Introduction 
1.1 Obstructive Sleep Apnoea as a worldwide health challenge   
Obstructive sleep apnoea (OSA) is a serious, potentially life-threatening condition caused 
by recurrent episodes of total and/or partial upper airway (UA) collapse occurring during 
sleep, accompanied by oxyhaemoglobin desaturation, large intra-thoracic pressure 
changes and arousal from sleep and, in severe cases, hypercapnia [1].  OSA is the most 
common respiratory sleep disorder and its prevalence is increasing due to the obesity 
epidemic and aging population [2, 3].  It has been estimated that symptomatic OSA affects 
up to 10% of middle-aged men and 3% of middle-aged women [3, 4], and it is associated 
with multiple comorbidities, including arterial hypertension [1], arrhythmias [5], coronary 
artery disease [6], right heart failure [7], stroke [8], and metabolic diseases (i.e. metabolic 
syndrome, impaired glucose tolerance, and diabetes mellitus) [1, 9], which concur to 
worsen prognosis. Untreated OSA has been linked to neurocognitive impairment and 
motor vehicle accidents [10, 11].  
Currently, continuous positive airway pressure (CPAP) represents the first line therapy, 
recommended by guidelines for treatment of patients with moderate-to-severe OSA [12, 
13].  CPAP aims to maintain upper airway patency by providing an air splint [14]. It 
reduces snoring, the apnoea/hypopnea index (AHI), and daytime sleepiness; furthermore, 
it improves neurocognitive function, driving risk, and sleep-related quality of life [15, 16]. 
CPAP may also reduce long-term cardiovascular risk in patients with OSA [17].  However, 
recently McEvoy et al. in the Sleep Apnea cardioVascular Endpoints (SAVE) trial [18] 
reported that adding CPAP to usual care, despite being associated with a reduction in 
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symptoms of daytime sleepiness and improving health-related quality of life, mood, and 
work attendance, did not reduce the risk of serious cardiovascular events compared to 
usual care alone.  This outcome could be explained by the limited adherence to CPAP 
treatment. In clinical services, low adherence to treatment occurs in up to 40-50% of the 
patients with OSA; in the SAVE trial the mean CPAP usage at 1, 6, and 12 months was 4.4 
± 2.0, 3.8 ± 2.3, and 3.3 ± 2.4 h/night, respectively. Considering that approximately only half 
of the OSA patients continue to use prescribed CPAP reliably long-term [12, 19] it is likely 
that a large portion of sleep apnoea patients are inadequately treated.  In such cases 
therapeutic alternatives to CPAP are required [12].  These include “sleep hygiene” (i.e. 
avoiding alcohol and sedatives), weight loss, mandibular advancement devices [20], 
positional therapy, and upper airway (UA) surgery [12].  However, these alternative 
measures are usually not comprehensive and definitive solutions, as they have been 
demonstrated to be effective in specific and selected cases; it has also to be considered that 
UA surgery has operative risks and potential associated morbidity.  
Responding to the high prevalence of untreated OSA and its impact on worldwide 
healthcare resources, a new type of treatment has been refined in recent years.  This 
involves use of electrical stimulation of the upper airway dilator muscles (Figure 1). 
In this review, the aim is to describe the evidence related to electrical stimulation of 
the UA dilator muscles in OSA in clinical practice.   
 
1.2 Neuromuscular tone of the upper airway and the pathophysiology of Obstructive 
Sleep Apnoea 
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Several decades ago, Remmers et al. reported a direct relationship between loss of 
genioglossus muscle activation during sleep and UA collapsibility in patients with OSA 
[21]; this seminal observation led to the hypothesis that OSA could be treated by electrical 
stimulation of the parapharyngeal muscles with transcutaneous, intraoral, or 
intramuscular electrodes [22, 23]. 
The anatomy of the upper airway is complex, as is the function, required for swallowing, 
respiration, and vocalization, which is related to the tightly controlled and complex motor 
tasks required for speech.  In human beings, UA obstruction during sleep is more 
prevalent than in other primates because the hyoid bone, a key anchor for pharyngeal 
dilator muscles, is not rigidly attached to skeletal structures. The human pharynx has no 
rigid support except at its cranial and caudal ends, where it is anchored to bone (in its 
upper side) and cartilage (larynx) caudally.  Therefore, pharyngeal cross-sectional area 
will vary with intra-luminal pressure [24, 25].  Studies using nasal pharyngoscopy, 
computer tomography (CT) and magnetic resonance imaging, or pharyngeal pressure 
monitoring, have shown that closure occurs in most subjects with OSA at one or more sites 
within the oral pharyngeal region, and that this region may be narrower in OSA patients 
compared to controls during wakefulness [26 – 29].  Although the retropalatal region of 
the oropharynx is the most common site of airway collapse, narrowing is a dynamic 
process, varying markedly among and within subjects and often including the retroglossal 
and hypopharyngeal areas [30, 31].  Neuromuscular control of breathing during sleep also 
plays a key role in OSA pathogenesis, e.g. central respiratory output, tonic activity of 
pharyngeal dilator muscles activity, arousal threshold and loop gain. The concept of ‘loop 
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gain’ is an engineering term, which defines the ‘gain’ of the negative feedback loop that 
regulates ventilation in response to a ventilatory disturbance [32]; if the magnitude of the 
increase in ventilation is greater than or equal to the magnitude of the preceding apnoea or 
hypopnea, i.e. a high loop gain, then the system is highly unstable and will fluctuate 
between hypo- and hyperventilation [33]. There are two types of control system gain, the 
controller gain (the control of variables relating to hypercapnic and hypoxic ventilatory 
responses) and the plant gain (the ability to eliminate CO2 and the size of oxygen stores), 
and they are major determinants of loop and ventilatory stability [34]. Sleep reduces 
controller gain relative to wakefulness, and, more importantly, upper airway tone, 
particularly in rapid eye movement (REM) sleep. A high loop gain promotes recurrent 
apnoea as a response to an initial disturbance, such as a sigh, because it is 
overcompensated, while a low loop gain inhibits subsequent variability in the breathing 
pattern [35]. Many patients with severe OSA have a high loop gain, as determined by the 
propensity for periodic breathing observed during ventilatory assist [36] or a greater 
ventilatory response to carbon dioxide (CO2) [34, 37].  
Multiple parapharyngeal dilator muscles work together to counteract the dual forces of 
negative intraluminal pressure from diaphragmatic excursion and positive extraluminal 
tissue pressure [25].  The genioglossus is the largest and strongest UA dilator.  The 
activation of noradrenergic neuron can selectively stimulate the genioglossus muscle, but 
the mono-aminergic neuron activity may decrease the dilating force of the UA when the 
noradrenergic neuron is inhibited during sleep [38].  Activation of the genioglossus muscle 
alone can reduce collapsibility but it may not always prevent significant obstruction [39]; 
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In individuals with a collapsible UA, dilating forces are represented by several other 
groups of motoneurons and the muscles they innervate, including motor trigeminal (V), 
facial (VII), glossopharyngeal (IX), motor vagal (X), and hypoglossal (XII) nerves.  Muscles 
regulating lung volume, neck and jaw position also contribute to UA patency, and thus 
motoneurons located in the cervical ventral horn impact on UA patency [25].   
In patients with OSA, the presence of cranial anatomic dysmorphisms, reduced tone of 
parapharyngeal dilator muscles (secondary to aging, alcohol assumption [40 – 41], 
smoking [42, 43], increased systemic inflammation [44]), and the higher positive 
extraluminal tissue pressure due to fat deposition on the neck, are important contributory 
factors that determine the onset of recurrent episodes of apnoea and/or hypopnoea during 
sleep.  The SPAtial Modulation of Magnetization (SPAMM) technique allows 
quantification of respiratory-related movement of the UA soft tissue displacement; using 
this method, it has been demonstrated that a high AHI (> 50 events/hour) is associated 
with minimal movement of the posterior tongue and the lateral walls of the nasopharynx 
during wakefulness [45].  
Starting from this known pathophysiology, several techniques to stimulate the 
muscles of the upper airway with electric current to increase neuromuscular tone and 
maintain UA patency during sleep have been developed.  
 
2. Electrical stimulation of the upper airway and its role in clinical practice for the 
treatment of Obstructive Sleep Apnoea 
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In recent years, several methods to stimulate parapharyngeal muscles have been 
developed [46] and refined as discussed in the next sections.   
 
2.1 Non-invasive methods for upper airway stimulation  
In 1989 Miki et al. described the effect of genioglossus electrical stimulation in anesthetised 
dogs [47]; they observed improved UA patency with graded increases in stimulation 
frequencies in awake, spontaneous breathing animals.  They also conducted the first 
experiment in humans to verify the tolerability and efficacy of UA stimulation [48]: six 
OSA patients underwent percutaneous electrical stimulation of the genioglossus during 
sleep.  Compared to control nights, the authors demonstrated that submental stimulation 
significantly improved AHI, longest apnoea duration, and number of times per hour that 
oxygen saturation dropped below 85%, thus proving the concept that this stimulation can 
reduce the incidence of apnoea episodes and promote deeper sleep. No adverse side 
effects were reported. An apnoea demand-type of stimulator, hence, may be an effective 
non-invasive treatment for OSA.  These early favourable results [48], however, could not 
be reproduced by subsequent studies in other centres performed with either external or 
percutaneous electrical stimulation of UA.  Successful stimulation of UA muscles and 
relief of UA obstruction without causing arousal from sleep could not be achieved with 
submental or intraoral stimulation [49], neither using submental electrodes or fine wire 
electrodes placed into the neurovascular bundle [50], nor with transcutaneous electrical 
stimulation applied in the submental or infrahyoid regions [51].  In particular, contrary to 
the first results [49], in 1992 Edmonds et al. showed that, despite similar electrode 
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placement and stimulation parameters, transcutaneous electrical stimulation applied in 
the submental and subhyoid regions in eight adults affected by OSA failed both to prevent 
the onset of UA collapse and the re-establishment of UA patency when stimulation was 
begun after apnoea onset during sleep. Moreover, when applied during wakefulness, 
transcutaneous stimulation did not provide UA enlargement as evaluated by CT [51].  
According to Decker et al. [50] the application of surface stimulation had inconsistent 
effects during apnoeic events, leading to termination of the apnoeas only in 22% of the 
cases; fine-wire functional electrical stimulation also had a limited impact, terminating 
23% of the apnoeic events.  They concluded that during sleep subjects tolerate both surface 
and fine-wire functional electrical stimulation at higher stimulus intensity than during 
wakefulness.   However, both approaches were judged to have an inconsistent effect on 
apnoeas during sleep [50].  In 1994, Hida et al. reported the effect of submental stimulation 
applied during five consecutive nights in eight OSA patients, and during two consecutive 
nights in five controls.  They found a positive effect of electrical stimulation in terms of 
improvement in AHI (53.8 ± 7.0 vs 27.3 ± 5.7 events per hour, p<0.01), total apnoea 
duration (41.1 ± 6.1 vs 17.6 ± 3.9% of total sleep time, p<0.01), mean duration of apnoea 
(27.4 ± 3.2 vs 23.0 ± 2.1 seconds, p<0.05), and oxygen saturation (SaO2) < 85% events/hour 
(32.5 ± 7.0 vs 11.3 ± 3.3, p<0.01): all parameters significantly improved during the fifth 
night of stimulation [52].  A year later, another study could not confirm the effectiveness of 
UA electrical stimulation in OSA. Using both submental and intraoral electrodes when 
awake and during sleep, in seven patients with severe OSA (mean respiratory disturbance 
index, RDI, 55 ± 6 per hour of sleep), Guilleminault et al. did not find changes in the 
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number of apnoeas and hypopnoeas, amount of oxygen desaturation, and mean duration 
of respiratory events, compared to baseline measurements [49]. Although they concluded 
that intraoral stimulation could act on dilator muscles, the complex muscle structure 
within the tongue may have multiple roles and could modify the UA shape without 
opening the UA.  In order to elucidate whether the co-activation of both the tongue 
protrudor and retractor muscles decrease the compliance of the retroglossal airway wall, 
Isono et al. [53] performed electrical stimulation of the tongue by two intraoral electrodes 
bilaterally in seven male OSA patients. Measuring pharyngeal cross-sectional area, the 
authors found that this procedure did not further dilate the oropharyngeal area with 
higher pressures, although the oropharyngeal area increased during stimulation with 
lower pressures (0.8 ± 9.0 vs 1.7 ± 1.8 cm2, p<0.05) [53].  Based on these results, in 2001 
Oliven et al. [54] undertook a study in which seven healthy volunteers and six OSA 
patients underwent electrical stimulation of the sublingual surface; the results showed that 
stimulation of the tongue improved airflow during sleep it was unsuccessful in reopening 
the UA in the presence of complete apnoea [54].  This study did not assess the tolerability 
or the potential clinical efficacy of UA electrical stimulation and was designed to verify the 
site within the UA that could respond best to stimulation.  More recent studies have been 
designed to assess the potential clinical role of electrical stimulation of UA, both in terms 
of efficacy and of patient comfort.  In 2008, Hu et al. [55] developed a percutaneous 50 Hz 
biphasic electrical nerve stimulator in which the intensity of stimulation could be 
regulated automatically to meet the needs for clinical treatment.  Biphasic electrical 
current pulses with equal electrical charge were used to avoid tissue injury during long-
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time stimulation.  The electric tension was 12-80 V peak-to-peak and the intensity levels of 
stimulation were individually set up during wakefulness in each subject.  Twenty-two 
OSA patients (six with severe OSA) were studied: the results showed that the mean of 
RDI, oxygen desaturation index (ODI), and longest apnoea significantly decreased (30.9 to 
12.5 events per hour, 33.0 to 18.6 events per hour, and 57.6 to 29.5 seconds, p<0.01 
respectively) [55]. In 2011, Steier et al. reported similar results in terms of improved ODI 
and AHI, and improvement in oxygen saturation [22]: using continuous transcutaneous 
submental 30-Hz electrical stimulation - the mean current was 10.1 (3.7) mA - in eleven 
patients with known OSA during one monitored night of sleep they confirmed that 
stimulation of the genioglossus muscle caused a measurable and reproducible contraction 
of the tongue and pharyngeal structures, reducing the RDI (28.1 to 10.2 events per hour, p 
= 0.002), ventilatory load and neural drive [22].  
Although the promising results from these studies support the potential role of 
transcutaneous electrical stimulation as a treatment in OSA, the previous studies had 
important limitations, particularly the absence of well-matched control groups.  To 
address this limitation, a randomised sham-controlled trial of transcutaneous electrical 
stimulation in OSA (TESLA trial) has been conducted and recently published [56].  The 
study was of 36 patients affected by moderate-to-severe or symptomatic mild obstructive 
apnoea, with an AHI median of 28.1 (interquartile range, IQR 19.0–57.0) and ODI median 
of 25.7 (IQR 16.0–49.1) events per hour, who were randomly assigned to one night of sham 
and one night of electrical stimulation delivered by surface electrodes attached bilaterally 
midway between the chin and the angle of the mandible in the submental area 
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(stimulation patches of 4 x 4 cm). Between stimulation and sham nights there was a wash-
out period of at least three nights. During active treatment (current of 626.1 μA (409.8 
mA)), the primary outcome of the trial, the ODI, improved modestly, by a mean of 4.1 
events per hour (95% confidence interval, CI −0.6 to 8.9, p=0.026) for the whole group, 
when compared with sham stimulation; no differences were observed in the oxygenation 
levels and there were no significant improvements in the AHI. Although the total AHI did 
not change during stimulation, there was a shift in the ratio from obstructive apnoeas to 
hypopnoeas when electrical current was applied, indicating an incomplete resolution of 
the UA obstruction during apnoeas (Figure 2). However, 47.2% of the patients were 
identified as responders in that they experienced an improvement in the AHI by > 50% or 
in the ODI >25% or to an AHI or ODI <5 events per hour. In this subgroup, the ODI was 
reduced by 10.0 (95%CI 3.9 - 16.0) events/hour and the AHI by 9.1 (95%CI 2.0 – 16.2) 
events/hour).  The patients’ device acceptance was good with patients reporting no skin 
discomfort or unpleasant sensations at night; there was no difference in subjects’ 
perceived sleep quality between the sham stimulation and the active treatment.  Moreover, 
the patients reported an improvement of their dry mouth after active treatment. This 
randomised controlled study also demonstrated that transcutaneous electrical stimulation 
of the UA dilator muscles in OSA can be safely delivered throughout the whole night and 
is useful to reduce the RDI, even though only modestly, in unselected OSA patients [56].   
In 2016, Chwieśko-Minarowska et al. [57] published a prospective study and its objective 
was to compare the effects of daytime transcutaneous electrical stimulation of the 
genioglossus muscle and CPAP therapy on the quality of sleep, in patients with OSA. 
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They found that electrical stimulation resulted in a decrease in Pittsburgh Sleep Quality 
Index (PSQI) values (p=0.012), but did not cause significant changes in ESS and AHI scores 
(p>0.05), in turn, a decrease in ESS and AHI (p>0.001), but not PSQI values (p = 0.089), was 
observed after CPAP therapy. Finally, Campbell et al. [58] surveyed 162 patients with OSA 
and the most preferred therapeutic modality was transcutaneous electrical stimulation of 
the genioglossus muscle (56.7%), followed by hypoglossal nerve stimulation (HNS) 
(21.7%), CPAP (17.8 %) and mandibular advancement device (3.8%). 
Well-designed future studies should focus on prospective identification of 
responders. It is likely that this method is more effective in OSA patients with an anterior 
pharyngeal wall collapse, and less efficacious in patients with excessive adipose tissue, 
large tonsils, and adenoids, or other anatomic abnormalities. This may explain the failure 
to respond to this method in some patients [50]. In addition, there are no data on the long-
term acceptability and compliance yet. 
In summary, well-designed studies, including larger groups of patients, are needed 
to determine the efficacy of this type of treatment, its safety and tolerability, and the 
optimal duration of electrical stimulation and to identify the individuals with OSA who 
may benefit.  
 
2.2 Invasive methods for electrical stimulation of the upper airway  
Following the promising results derived from implantable nerve stimulation technology in 
other medical conditions (e.g. sacral nerve stimulation for incontinence [59], vagal nerve 
stimulation for seizures [60], spinal cord stimulation for pain [61], and deep brain 
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stimulation for tremor [62]) [63], Schwartz et al. [64] tried to selectively stimulate the 
hyoglossus and styloglossus muscles (that retract the tongue), and the genioglossus (that 
protrudes the tongue) during sleep using fine-wire electrodes placed intramuscularly via 
an oral approach.  They reported a significant improvement in maximal inspiratory 
airflow during protrusor stimulation, with no arousal from sleep; however, no attempts 
were made to measure UA collapsibility.  
Oliven et al. [65] demonstrated that, in 8 anesthetised dogs, selective intramuscular 
stimulation of the hypoglossus significantly lowered the UA collapsibility, defined and 
measured as the “critical” occlusion pressure (Pcrit).  The same group studied the response 
to electrical stimulation in the UA pressure-flow relationship during sleep with an 
implanted hypoglossal nerve stimulator in five patients; fine-wire electrodes were inserted 
into the genioglossus.  The results confirmed that Pcrit decreased similarly during both 
hypoglossus and genioglossus electrical stimulation (ΔPcrit was 3.98 ± 2.31 and 3.18 ± 1.70 
cmH2O, respectively) [66].  
However, only in 2001 was the first pilot study in human beings published that studied 
the effect of implantable HNS on OSA [67].  After the development of new implantable 
hypoglossal nerve-stimulating devices, Schwartz et al. [67] conducted a clinical trial to test 
this device (Inspire I, Inspire Medical Systems™, Maple Grove, MN, USA) in eight apnoeic 
patients for six months. The system consisted of three components: a tripolar half-cuff 
nerve stimulation electrode, an implantable pulse generator, and a respiratory pressure 
sensor placed against the pleura to detect respiratory effort. “End expiration” triggered the 
implantable pulse generator at the onset of inspiration. Implantation of the HNS required 
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general anaesthesia. Sleep studies were performed at 1, 3, and 6 months postoperatively 
and seven of the eight participants had significant reductions in their AHI and in the 
overall group non-rapid eye movement (REM) sleep AHI improved from 52.0 ± 20.4 to 
22.6 ± 12.1 (p<0.001) events per hour. All participants tolerated stimulation once 
parameters were appropriately adjusted.  Despite the encouraging results, broken 
electrodes and sensor malfunction occurred in five of eight participants, thus precluding 
use beyond the 6-month study period [67]. 
Addressing the technical limitations of this study, multiple investigators and medical 
device companies spent years improving the product. In 2011, Eastwood et al. [68] 
reported on the safety and effectiveness of a new generation implantable hypoglossal 
nerve stimulator therapy system (HGN System, Apnex Medical™ Inc, St Paul, MN, USA) 
in a phase II trial carried out at four Australian centres.  Twenty-one patients with 
moderate-to-severe OSA who were unable to tolerate CPAP underwent surgical 
implantation of the dual respiratory sensing leads, which were tunnelled subcutaneously 
along the costal margin.  These sensors functioned as thoracic impedance sensors and 
were used to determine respiratory effort.  Intra-operative fluoroscopy was used to 
confirm placement of the electrode cuff by demonstrating an expansion of the retroglossal 
airway with device activation.  Sleep studies were performed at 1, 3, and 6 months.  
Nineteen of the 21 participants in the study had baseline and 6-month polysomnography, 
and showed a significant improvement from baseline in AHI (43.1 ± 17.5 to 19.5 ± 16.7 
events per hour, p<0.05) and Epworth Sleepiness Scale (ESS) score (12.1 ± 4.7 to 8.1 ± 4.4, 
p<0.05).  Only two adverse events were reported: an infection requiring device removal 
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and stimulation lead cuff dislodgement requiring replacement [68].  Testing the same 
device, Goding et al. [69] enrolled 26 OSA patients with the aim of characterizing the 
changes in the antero-posterior dimensions of both the retro palatal and retro lingual 
airway space of the pharynx and hyoid bone position during HNS (Apnex Medical™ 
Hypoglossal Nerve Stimulation system). All participants were examined by 
cinefluoroscopy videos under general anaesthesia before and during bursts of electrical 
stimulation; an increase in retro lingual airway space (9 ± 3 mm) was observed and the 
anterior displacement of the base of the tongue with stimulation occurred at an average 
stimulation level of 1.2 ± 0.3 mA.  An enlargement of the retro palatal airway was seen in 
65% of the cohort; the average increase was 5 ± 3 mm. There was a trend (without 
significance) towards increased body mass index (BMI) in those participants who failed to 
show an expansion of the retro palatal airway. Anterior displacement of the hyoid 
occurred in 92% of participants [69]; the hyoid bone is attached to soft tissue structures 
related to the pharynx and has been the target for treatment of OSA. Its anterior 
displacement can be achieved using HNS, which leads to anterior displacement of the base 
of the tongue and an increase in the anterior-posterior retrolingual airway dimensions of 
the pharynx [69].  
In 2012, another group [70] carried out two consecutive open prospective studies with 
another device, the Inspire II Upper Airway Stimulation system (Inspire Medical 
Systems™, Maple Grove, MN, USA), which was in a similar way implanted as the HGN 
system described above with the exception that this device had only a single sensor for 
respiration.  The study was divided into two parts; in the first, the therapeutic feasibility 
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and safety of UA stimulation in 22 participants with OSA was assessed and predictive 
factors for therapeutic success were analysed. After 6 months of follow-up, only six 
subjects showed a significant and sustained reduction in the AHI compared to baseline; 
these patients had a BMI > 32 kg/m2 and an AHI > 50 (p<0.05) and were more likely to have 
complete concentric palatal collapse. In the second part of the study, patients (n = 8) were 
prospectively selected for a body mass index (BMI) ≤ 32 kg/m2, an AHI between 20 and 50 
events per hour, and a non-complete concentric pattern of palatal collapse during drug-
induced sedation endoscopy (DISE); also in these subjects, an improvement in the AHI 
was found (from 38.9 ± 9.8 to 10.0 ± 11.0 per hour; p<0.01) at 6 months post-implant. The 
ESS and Functional Outcomes of Sleep Questionnaire (FOSQ) improved significantly in 
the treated patients [70].  
The precise placement of the cuff electrode on selected branches of the hypoglossal nerve 
is essential for the successful delivery of UA electrical stimulation. The optimal site of 
stimulation a functional breakpoint between retractors and protrusors along the course of 
the hypoglossal nerve is determined by excluding the most distal branch, which typically 
innervates the anterior portion of the hyoglossus muscle [71, 72]. With the aim to 
selectively stimulate the proximal trunk of the hypoglossus nerve, in 2013, another 
neurostimulation device, ImThera aura6000TM (ImThera Medical Inc., San Diego, CA, 
USA) system was developed and tested, and the results of the phase I and II trials were 
reported by Mwenge et al. [73]. Currently, there is an ongoing multi-centre phase III trial. 
The ImThera aura6000TM device is characterised by continuous nerve stimulation without 
a respiratory sensing lead, but alternates electrical stimulation impulses through different 
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electrode configurations to rest some neuromuscular groups while others are being 
stimulated. The electrode cuff is furled around the hypoglossal nerve near the middle 
tendon of the digastric muscle, so that the six stimulating electrodes are radially in contact 
with the cylindrical body of the proximal hypoglossal nerve.  The initial open-label, single-
site, single-arm study was conducted to determine safety and efficacy of ImThera 
aura6000TM in 13 patients with untreated moderate-to-severe OSA [73]. After 12 months of 
follow-up the authors describe a significant decrease in the AHI from 45.2 ± 17.8 (baseline) 
to 21.0 ± 16.5 per hour (p<0.001), in the ODI from 29.2 ± 19.6 to 15.3 ± 16.2 per hour 
(p=0.001), and in the arousal index from 36.8 ± 12.5 to 24.9 ± 13.7 events per hour  
(p=0.001). However, there was no improvement in the ESS (from 11 ± 7 to 8 ± 4, p=0.09). 
Tolerability and safety of the hypoglossal neurostimulation was judged to be acceptable, 
stimulation was neither painful nor did it wake patients who complied with therapy. 
However, there were two cases of transient ipsilateral hemi-tongue paresis; post-operative 
swelling lasted for 2 weeks in one patient; three leads broke in two patients; one patient 
had a Twiddler’s syndrome and the implanted pulse generator was manually 
repositioned, and the stimulation continued without further trouble [73]. 
In 2014, the largest prospective trial to date was published: the Stimulation Therapy for 
Apnea Reduction (STAR) trial [74]. 929 patients were enrolled in the study, 724 were 
screened, and, finally, 126 were eligible and implanted the device. These subjects 
presented moderate-to-severe OSA (AHI 20–50 events per hour), CPAP intolerance, BMI ≤ 
32 kg/m2, and absence of a complete circumferential pattern of palatal obstruction during 
DISE. They underwent surgical implantation of the HNS system (Inspire II Medical 
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Systems™, Maple Grove, MN, USA) and were followed for 12 months to assess 
effectiveness and adverse events. Devices were titrated in the sleep laboratory during 
polysomnography to optimize comfort and effectiveness. The primary (AHI, ODI) and 
secondary outcomes measures (ESS, FOSQ) all demonstrated clinically and statistically 
significant improvements, in particular the median AHI score at 12 months decreased by -
68%, from 29.3 to 9.0 events per hour (p<0.001), the ODI score decreased by -70%, from 
25.4 to 7.4 events per hour (p<0.001). The overall rate of serious adverse events was less 
than 2%; only two patients had device-related adverse events requiring repositioning and 
fixation. No permanent hypoglossal nerve weakness, no serious device-related infection 
requiring removal, and significantly less postoperative discomfort compared to traditional 
pharyngeal or maxillo-facial sleep apnoea surgeries were reported. A third of the 
participants reported minor tongue discomfort due to stimulation itself or abrasion of the 
tongue on an adjacent tooth. Most of these local side effects resolved with adjustment of 
stimulation parameters or in some cases a dental guard. Adherence was excellent by self-
report (86% of participants using the therapy nightly at the 12 months) but detailed 
objective data monitoring was limited [74].  Successively [75], the first 46 therapy 
responders from the prospective STAR trial entered a randomized controlled therapy 
withdrawal phase. The patients were assigned to continue or stop with the treatment 
(‘‘ON’’ or ‘‘OFF’’) and, eventually, they were re-assessed. The results indicated that 
patients in whom the treatment was discontinued still had moderate-severe OSA. The AHI 
deteriorated with the treatment discontinued (from 7.6 ± 4.0 to 25.8 ± 16.2 events per hour, 
p<0.05). Similarly, self-reported secondary measures (ESS and FOSQ) that had initially 
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improved deteriorated again when therapy was switched off.  Furthermore, in this study, 
for the first time, the authors highlighted the clinical effect of the HNS on the blood 
pressure. As mentioned above, OSA is associated with increases in blood pressure through 
several mechanisms, including activation of the sympathetic nervous system, oxidative 
stress, and catecholamine metabolism dysregulation [76]. Whereas a lowering effect of 
CPAP therapy on blood pressure reduction has been demonstrated [77], data on the 
impact of HNS on blood pressure are limited. Therefore, Woodson et al. [75] reported that, 
even though patients were normotensive, systolic and diastolic blood pressures in the on-
going treatment group were significantly lower at 12 and 18 months, whereas blood 
pressure did not change in the group that discontinued treatment.  
A second single-arm, prospective interventional trial was performed using the Apnex™ 
HGN system device by Kezirian et al. [78]. They reported the 12-months outcomes in a 
group of 31 patients with moderate-to-severe OSA. Primary outcomes included both 
objective and subjective measurements. Across all subjects, the AHI decreased from 45.4 ± 
17.5 to 25.3 ± 20.6 events per hour (p<0.001) and the FOSQ score improved from 14.2 ± 2.0 
to 17.0 ± 2.4 (p<0.001). Interestingly, subjects with a BMI ≤ 35 kg/m2 (68%, 21/31) 
demonstrated significantly greater reduction in the AHI and better improvement in 
symptoms at 12 months compared to the subgroup of patients with a BMI > 35 kg/m2. 
Patients demonstrated excellent compliance, using therapy during 86% of nights for an 
average of 5.4 hours per night. Within the first 6 months, three serious device-related 
adverse events occurred: an infection requiring device removal and two stimulation lead 
cuff dislodgements requiring replacement [78].  
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The analysis of clinical aspects and outcomes of HNS implantation outside the context of a 
clinical research trial was published by Kent et al. [79], presenting results from a 
retrospective data collection in a single academic sleep centre. The authors showed that 
HNS therapy, using the Inspire device (Inspire Medical Systems™, Minneapolis, 
Minnesota) was associated with good adherence (mean 7.0 ± 2.2 h/night), low morbidity, 
and significantly improved subjective and objective OSA outcome measures. In a group of 
twenty patients with severe OSA, previously treated with UA surgery, or CPAP, or BiPAP, 
or oral appliance therapy, the authors found that after a post-operative period of about 3 
months, most of the patients presented with a good response to HNS in terms of AHI 
(reduction of the AHI from 33.3 ± 13.0 to 5.1 ± 4.3; p<0.001) and sleepiness (reduction of the 
ESS from 10.3 ± 5.2 to 6.0 ± 4.4; p<0.01). Three patients had HNS related problems, two 
patients developed a seroma at the incision site in the immediate postoperative period, 
and one patient experienced prolonged incisional discomfort). These data suggest that 
HNS treatment can be used in routine clinical practice outside of a clinical trial setting [79].  
The importance of evaluating the technical aspects of the surgical procedures was 
summarised in a recent review by Murphey et al. [80], based on the transition of HNS 
systems from clinical trials to US Food and Drug Administration (FDA)–approved 
commercial implants. The goal of the review was to describe the learning curve in the 
surgical procedures using the Inspire device (Inspire Medical Systems™, Maple Grove, 
MN, USA) to determine the effect of experience on surgical procedure time and 
complication rates. The authors examined data from 22 study centres and concluded that 
the implant surgery time decreased significantly with experience (after the first five 
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implants); however, surgeon experience did not appear to improve outcomes 
(complication rates and post-operative pain); the safety profile and peri-operative 
morbidity were acceptable and compared favourably to other implantable device 
procedures. 
 
Data on the Inspire™ and Apnex™ devices have described the acute response to 
hypoglossus stimulation [81]. Unilateral stimulation of the hypoglossal nerve during sleep 
in patients with OSA results in improved inspiratory airflow with increasing stimulation 
intensity. Airflow returns to baseline before and after the stimulated breath suggesting 
that hypoglossus nerve stimulation exerts a direct effect on lingual muscles and airway 
patency without arousing patients from sleep.  The stimulation technique of the ImThera 
aura6000TM device, as mentioned above [71], is continuous; this modality enables a more 
coordinated activation of the tongue muscles. Rodenstein et al. [82], in a brief 
communication published after the conclusion of 12-month single-site clinical trial [62], 
speculated that stimulation strengthens the tongue muscles, producing an additive effect 
that persists after stopping stimulation. However, this is speculation based on findings 
during the first night off therapy in 10 patients. The tonic-type stimulation might have 
modified the neural pattern of stimulation of the tongue muscles, either by modifying the 
agonist–antagonist balance of forces, by modification of the activated motor units, or by 
impact on the associated cortical areas. At the moment, these hypotheses remain 
speculative, but underline that neural stimulation can result not only in direct muscle 
function, but also in altered neuromuscular tone [82].  
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In summary, HNS for the treatment of OSA is a relatively safe and effective 
alternative for improving OSA outcomes in individuals with moderate-to-to severe OSA 
who have failed conventional medical treatment. HNS leads to a clinically significant 
decrease in observed mean AHI, ODI, and ESS, combined with improvements in several 
quality-of-life scales. Responders are more likely to be less obese and have less severe 
OSA, which is also true for the transcutaneous approach. Specific technical features will 
need to be tested to improve implantable devices effectively and different types of 
stimulation need to be systematically assessed.   
 
2.3 Hybrid methods 
In addition to either the invasive and the non-invasive methods of electrical stimulation 
new “hybrid” treatments combining the two methods have been proposed.  One of these 
devices is the so-called Nyxoah system (Nyxoah S.A. Brussels, Belgium) and consists of a 
small neurostimulator for the distal branches of the hypoglossal nerve. The device 
contains two main different parts: the Genio™ Implantable Stimulator (Nyxoah S.A. 
Brussels, Belgium), an implanted device placed in the submental area adjacent to the 
genioglossus muscle through surgical procedure, and an external activation chip attached 
to the skin with a disposable patch, which contains batteries and activates the implantable 
stimulator through radio frequencies.  The technique is minimally invasive when 
compared to other hypoglossal neurostimulation systems; there is no implanted lead or 
battery unit, which is claimed to reduce the risk of surgical re-intervention. From a 
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physiological standpoint it can stimulate the hypoglossal nerve bilaterally. However, there 
are sparse data on the efficacy of such hybrid methods in patients with OSA. A clinical 
trial has been concluded (https://clinicaltrials.gov/ct2/show/NCT02312479) and the results 
are expected to be published.  
 
3. Future developments 
Electrical stimulation of the upper airway dilator muscles in OSA can be considered as an 
evolving non-CPAP therapy. There are new data available from randomised controlled 
trials for both invasive and non-invasive electrical stimulation [56, 73]. These trials suggest 
that the treatments are effective in a selected cohort of patients, particularly those who are 
less obese and who have less severe OSA. Electrical stimulation is well tolerated if 
stimulation intensity if titrated properly to avoid waking the patients. For invasive 
stimulation, improving surgical procedures and quality will further reduce complications. 
Recent studies [74] have shown lower rates of adverse events compared to previous trials 
[73]. In the STAR trial the overall rate of serious adverse events was less than 2% with two 
out of 126 participants having a serious device-related adverse event requiring 
repositioning and fixation of the neurostimulator to resolve discomfort. Despite these 
promising results in terms of effectiveness, safety, and tolerability of UA electrical 
stimulation, the costs of devices and surgical procedures make this treatment limit 
accessibility in publicly funded healthcare systems. A full cost-effectiveness analysis to 
weigh costs and effectiveness has yet to be performed to demonstrate that UA electrical 
stimulation is a cost-effective treatment strategy for moderate-to-severe OSA patients 
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intolerant to CPAP therapy.  In a first attempt, Pietzsch et al. [83] have shown that UA 
stimulation on a willingness-to-pay threshold costs $50,000–$100,000/Quality Adjusted 
Life Year (QALY).  However, this study was conducted in the U.S. healthcare system, and 
the analysis only compared UA stimulation to no treatment. Other healthcare providers 
may have lower thresholds to define cost-effectiveness. 
 
Non-invasive electrical stimulation in OSA requires further validation of the results of the 
TESLA trial [56], which showed a rather modest improvement in both ODI and AHI in the 
whole cohort of patients but significant improvements in responder groups. In particular, 
better characterisation of responders requires further study, as well as the feasibility of 
long-term acceptability and outcomes of transcutaneous electrical stimulation in the 
domiciliary setting.  
In summary, there is accumulating evidence that electrical stimulation in OSA is a well-
tolerated and effective treatment in responders, which can help to address the problem of 
the large number of patients that fail, or do not tolerate, CPAP treatment. Electrical 
stimulation offers another option of non-CPAP therapy in the treatment possibilities for 
OSA. 
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4. Expert commentary: 500 -1000 words  
Treatment of OSA is recommended for patients symptomatic disease with symptoms of 
excessive daytime sleepiness and proven cardiovascular risk factors (i.e. arterial or 
pulmonary hypertension, ischemic heart or cerebral disease, arrhythmia, diabetes 
mellitus) regardless of severity. The first line therapy, together with measures of sleep 
hygiene, diet, and physical exercise, is CPAP therapy which is considered the gold 
standard. However, CPAP may not be tolerated and patients long-term compliance tends 
tends to be low. Although mandibular advancement devices can be used to treat mild 
OSA, alternative treatment strategies are required. Electrical stimulation of the upper 
airway has been developed to address this need.    
The available evidence on non-invasive and invasive strategies of electrical stimulation of 
the UA dilator muscles in OSA suggests that this type restores the physiological function 
of the UA dilator muscles during sleep. Nevertheless, there is a need for further research 
aimed at comparing these methods with conventional therapies (i.e. CPAP, oral 
appliances, and other surgical procedures) using a robust methodology to test feasibility 
and to establish cost-effectiveness. Future studies should concentrate on identifying 
potential responders to that treatment.  Moreover, further studies and clinical trials are 
needed to evaluate the long-term impact of these methods on blood pressure, metabolic 
and cardiovascular risk parameters linked to OSA.  
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Five-year view and future implication 
There is mounting evidence that electrical stimulation is a potential treatment for OSA 
patients who respond to this approach, and that allows clinical translational work to be 
delivered at the bedside. More data are required to study whether the promising results 
observed in randomised controlled trials can be replicated in clinical services. 
We speculate that in the near future, with the continuous improvement of devices, 
software and stimulation algorithms and with a better understanding of the phenotype of 
responders, electrical stimulation for OSA might be used in patients who do not tolerate 
CPAP, or for those with mild to moderate disease. Future revisions of international 
guidelines and recommendations for the treatment of OSA need to update the evidence 
provided by randomised controlled trials and summarised in this review, and this will 
promote the acceptance of electrical stimulation as alternative treatment to CPAP therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
28 
Key issues  
 Obstructive sleep apnoea (OSA) is a serious condition affecting sleep quality and 
causing symptoms like excessive daytime sleepiness, determining most of road 
traffic accidents. 
 Continuous positive airway pressure (CPAP) is the most effective treatment for 
OSA, however, long-term adherence is limited. 
 Alternative treatments like neuromuscular stimulation of the airway dilator 
muscles have been shown to be effective and are well tolerated. 
 The STAR trial confirmed that the stimulation of the muscles through an 
implantable stimulator of the hypoglossus nerve effectively improves OSA 
although cost implications have to be considered. 
 The TESLA trial has shown that stimulation of the upper airway dilator muscles 
through transcutaneous electrical current has a modest effect on OSA, but in a 
subgroup of patients the effect was clinically relevant; this approach was well 
tolerated but remains to be tested in the community setting. 
 Currently, there is a lack of evidence for hybrid devices, and further testing is 
required. 
 Future work could incorporate drug-induced sedation endoscopy to better 
understand favourable patterns of airway collapse with the aim to identify 
responders to electrical stimulation. 
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 Giving the rising evidence of the effectiveness of neuromuscular stimulation of the 
airway dilator muscles in OSA, future guidelines should consider the 
aforementioned studies and the recently changed scientific evidence. 
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